We retrospectively reviewed 104 biopsy specimens of previously untreated skin acute graft-versus-host disease (GVHD) within 100 days after allogeneic stem cell transplantation, and analyzed the relationship between types of infiltrating cells and clinical outcomes. Counting the total number of CD8+ T cells, CD163+ macrophages, and CD1a+ dendritic cells in 4 fields under original magnification ×200, the infiltration of more than 200 cells of CD163+ macrophages (many macrophages [MM]) was the only significant predictor for refractory GHVD (odds ratio, 3.79; 95% confidence interval, 1.22-11.8; P = .02). In 46 patients given steroid treatments, MM was the only significant predictor for refractory acute GVHD (odds ratio, 5.05; 95% confidence interval, 1.19-21.3; P = .03). Overall survival of patients with MM was significantly lower than that of those with an infiltration of less than 200 cells of CD163+ macrophages. Macrophage infiltration of skin lesions could be a significant predictive factor for refractory GVHD and a poor prognosis.

Macrophages are phagocytic cells with various abilities, such as phagocytosis, antigen-presenting, and secretion of cytokines.1,2  Recently, it was revealed in human sequential biopsy data that recipient macrophages contributed to acute graft-versus-host disease (GVHD) by antigen-presenting and secreting cytokines, causing the activation and proliferation of CD8+ T cells.3  We focused on macrophage involvement in acute GVHD, especially on the relationship between the macrophage infiltration of skin lesions and refractory GVHD.

Between January 1997 and October 2007 at the Japanese Red Cross Nagoya First Hospital, we used skin biopsy specimens within 100 days after allogeneic stem cell transplantation (allo-SCT) of skin lesions clinically considered acute GVHD without any GVHD treatment from 104 patients who underwent allo-SCTs. We analyzed the relationship between types of infiltrating cells and clinical outcomes by counting the total number of CD8+ T cells, CD163+ macrophages, and CD1a+ dendritic cells in 4 fields of a skin biopsy specimen under original magnification ×200. Immunohistochemical analysis using paraffin sections was performed using monoclonal antibodies against CD8, CD163, and CD1a (Novocastra). CD163 is a member of the scavenger receptor cystein-rich superfamily and is an exclusive marker for macrophages, playing a major role in the scavenging components of damaged cells.4,,7 

The endpoints of this study were the outcomes of acute GVHD and overall survival (OS). Acute GVHD was diagnosed and graded according to the consensus criteria.8  We defined refractory GVHD as that exhibited by patients who had persistent lesions after primary steroid treatments. To establish parameters, we analyzed the numbers of infiltrating CD8+ T cells (≤ 100/4 fields [few T cells; FT] vs > 100/4 fields [many T cells; MT]), numbers of infiltrating CD163+ macrophages (≤ 200/4 fields [few macrophages; FM] vs > 200/4 fields [many macrophages; MM]), disease risk (low vs high), human leukocyte antigen (HLA) disparity (match vs mismatch), donor source (related vs unrelated), graft source (bone marrow vs peripheral blood), age at allo-SCT (≤ 50 years vs > 50 years), conditioning regimen (conventional regimens vs reduced intensity regimens), and skin GVHD stage at biopsy (stages 1-2 vs stages 3-4). A significance level of P < .05 was used for all analyses, which were based on all data available as of August 31, 2008. Protocols were approved by the Japanese Red Cross Nagoya First Hospital's Institutional Review Board, and all patients provided informed consent in accordance with the Declaration of Helsinki.

Table 1 summarizes the characteristics of patients and information gathered about GVHD. We divided patients into 4 groups according to the amount of infiltrating cells (FM and FT, 60.6%; MT and FM, 18.2%; MT and MM, 10.6%; and FT and MM, 10.6%). We noted a striking difference among patients in the types of infiltrating cells in skin GVHD lesions (Figure 1A). The distributions of numbers of infiltrating cells also exhibited a considerably wide variety (Figure 1B). The median number of infiltrating CD8+ T cells was 65 (range, 2-305), that of infiltrating CD163+ macrophages was 132.5 (range, 38-372), and thatof infiltrating CD1a+ dendritic cells was 7 (range, 0-122). We used 3 skin biopsy specimens of drug rash from autologous transplantation patients as non-GVHD controls; the median numbers of CD8+, CD163+, and CD1a+ infiltrating cells were 11 (range, 6-15), 26 (range, 19-30), and 68 (range, 65-83), respectively. MT was correlated with an HLA mismatch (P = .047), grade III-IV acute GVHD (P = .03), and MM (P = .01), whereas MM was correlated with unrelated donor (P = .04), an HLA mismatch (P = .049), refractory GVHD (P = .004), and MT (P = .01) using χ2 analyses. The sensitivity and specificity of MT for refractory GVHD were 25.0% and 70.5% in all 104 patients, and 25.0% and 73.3% in 46 receiving steroids, whereas those of MM were 43.8% and 82.9%, and 43.8% and 86.7%, respectively.

Figure 1

Skin biopsy specimens, infiltrating cells, and overall survival. Immunohistochemical analysis of representative skin biopsy specimen (A), the cell count distribution of CD8+, CD163+, and CD1a+ cells (B), and the impact of MM on OS (C-D). (A) Tissue sections of skin biopsy were stained with hematoxylin and eosin (ai,bi,ci), or antibodies to CD8+ (aii, bii, cii), or CD163+ (aiii, biii, ciii) as detailed in “Methods.” Shown are representative specimens of an MT/FM patient (ai-iii), a MT/MM patient (bi-iii), and an FT/MM patient (ci-iii). Original magnifications ×200. (B) Distribution of infiltrating cell counts (Bi, CD8+; Bii, CD163; and Biii, CD1a). (C) OS according to CD163+ cell counts (≤ 200 [FM] vs > 200 [MM]) in all patients. OS of patients with MM was significantly lower than that of those with FM (FM: 66.2% ± 10.6% at 1 year and 58.3% ± 11.4% at 3 years, MM: 37.8% ± 21.0% at 1 year and 37.8% ± 21.0% at 3 years, respectively; P = .005). (D) OS according to CD163+ cell counts (≤ 200 vs > 200) in 46 patients undergoing steroid treatments. OS of patients with MM was significantly lower than that of those with FM (FM: 57.7% ± 17.1% at 1 year and 50.7% ± 17.4% at 3 years; MM: 18.2% ± 22.7% at 1 year and 18.2% ± 22.7% at 3 years, respectively; P = .002).

Figure 1

Skin biopsy specimens, infiltrating cells, and overall survival. Immunohistochemical analysis of representative skin biopsy specimen (A), the cell count distribution of CD8+, CD163+, and CD1a+ cells (B), and the impact of MM on OS (C-D). (A) Tissue sections of skin biopsy were stained with hematoxylin and eosin (ai,bi,ci), or antibodies to CD8+ (aii, bii, cii), or CD163+ (aiii, biii, ciii) as detailed in “Methods.” Shown are representative specimens of an MT/FM patient (ai-iii), a MT/MM patient (bi-iii), and an FT/MM patient (ci-iii). Original magnifications ×200. (B) Distribution of infiltrating cell counts (Bi, CD8+; Bii, CD163; and Biii, CD1a). (C) OS according to CD163+ cell counts (≤ 200 [FM] vs > 200 [MM]) in all patients. OS of patients with MM was significantly lower than that of those with FM (FM: 66.2% ± 10.6% at 1 year and 58.3% ± 11.4% at 3 years, MM: 37.8% ± 21.0% at 1 year and 37.8% ± 21.0% at 3 years, respectively; P = .005). (D) OS according to CD163+ cell counts (≤ 200 vs > 200) in 46 patients undergoing steroid treatments. OS of patients with MM was significantly lower than that of those with FM (FM: 57.7% ± 17.1% at 1 year and 50.7% ± 17.4% at 3 years; MM: 18.2% ± 22.7% at 1 year and 18.2% ± 22.7% at 3 years, respectively; P = .002).

Close modal

In 46 patients undergoing steroid treatments, the median date of the appearance of skin lesions was 17.0 days (range, 5-54 days), whereas that of skin biopsy was 27.5 days (range, 6-63 days) and that of the highest skin stage was 32.0 days (range, 9-68 days). Treatments for GVHD were considered for GVHD patients without spontaneous regression and with progression to a higher grade, except for those in which enhanced immunosuppression would not be preferable, such as encephalopathy resulting from calcineurin inhibitor or a pathologic diagnosis of intestinal transplantation-associated microangiopathy.9,10  The median interval from the initial clinical manifestation of GVHD to the primary treatments was 4.5 days (range, 0-97 days). The dose of prednisolone was 0.5 mg/kg in 4 patients, 1 mg/kg in 20 patients, 2 mg/kg in 19 patients, 500 mg/body in 1 patient, and 1000 mg/body in 2 patients. Only MM was identified as a negative predictive factor for refractory GVHD (Table 2). In 46 patients undergoing steroid treatments, only MM was identified as a negative predictive factor for refractory GVHD (odds ratio, 5.05; 95% confidence interval [CI], 1.19-21.3; P = .03).

In the Cox proportional hazard model, age more than 50 years, high risk, and MM were identified as significant risk factors by univariate analyses, with MM and high risk remaining a significant risk in a multivariate analysis (Table 3). OS rates were significantly higher in FM patients compared with those in MM (Figure 1C). Uncontrolled GVHD was the cause of 6 MM patients of 11 (54.5%) who died because of transplantation-related mortality (TRM), whereas in FM patients, 3 of 24 (12.5%) died because of uncontrolled GVHD. The causes of death for the 5 MM patients who did not die of uncontrolled GVHD were infection in 3 patients, intestinal transplantation-associated microangiopathy in 1 patient, and liver failure in 1 patient. In 46 patients who underwent steroid treatments, only MM was identified as a significant risk factor in the Cox proportional hazards model (Hazard ratio 3.25; 95% CI, 1.46-7.26; P = .004). OS rates were significantly higher in FM patients compared with those in MM (Figure 1D). Uncontrolled GVHD was the cause of 6 MM patients of 9 (66.7%) who died because of TRM, whereas in FM patients, 3 of 15 (20.0%) died because of uncontrolled GVHD.

Our study suggested that macrophages are involved in a specific type of acute GVHD that tended to be systemic and refractory to conventional therapies, such as corticosteroids or calcineurin inhibitors.11,13  Differences in treatment efficacy could be explained by the difference in infiltrating cell types. Although efforts have been made at predicting refractory GVHD,14,,17  no confirmed factor has been established to date. Our findings could prove to be a relatively simple and useful method directly related to the prognosis of patients.

Macrophages could not be completely suppressed by current therapies for acute GVHD mainly targeting T cells. Considered together with the fact that skin biopsies can be performed safely without any critical complications, our results support the importance of conducting skin biopsies of posttransplantation skin lesions. In cases where macrophage-dominant infiltration is observed in a skin biopsy specimen, macrophage-targeted therapies18,,,,23  could provide a clue to refractory GVHD.

In conclusion, macrophage infiltration of skin lesions after allo-SCT was shown to be a significant predictive factor for refractory GVHD, as well as being a negative prognostic factor for OS. Our results indicate the importance of skin biopsies after allo-SCT and suggest the possibility of developing infiltrating cell-based strategies.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

This study was supported in part by the Japan Leukemia Research Fund (S.N.) and in part by a Ministry of Health, Labor and Welfare of Japan Grant-in-Aid (K.M.).

Contribution: S.N., S.T., M.I., and K.M. designed the research; S.N., S.T., and M.I. analyzed and interpreted the data; S.N. and S.T. performed statistical analysis; and S.N., T.G., A.S., K.W., M.Y., N.I., S.T., M.S., Y.O., M.I., and K.M. collected clinical data and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Masafumi Ito, Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35 Michishita-cho, Nakamura-ku, Nagoya 453-8511, Japan; e-mail: itom@nagoya-1st.jrc.or.jp.

1
Gordon
S
The role of the macrophage in immune regulation.
Res Immunol
1998
149
7
685
688
2
Stoy
N
Macrophage biology and pathobiology in the evolution of immune responses: a functional analysis.
Pathobiology
2001
69
4
179
211
3
Haniffa
M
Ginhoux
F
Wang
XN
et al
Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation.
J Exp Med
2009
206
2
371
385
4
Kristiansen
M
Graversen
JH
Jacobsen
C
et al
Identification of the haemoglobin scavenger receptor.
Nature
2001
409
6817
198
201
5
Fabriek
BO
Dijkstra
CD
van den Berg
TK
The macrophage scavenger receptor CD163.
Immunobiology
2005
210
2-4
153
160
6
Moestrup
SK
Moller
HJ
CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response.
Ann Med
2004
36
5
347
354
7
Zaba
LC
Fuentes-Duculan
J
Steinman
RM
Krueger
JG
Lowes
MA
Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages.
J Clin Invest
2007
117
9
2517
2525
8
Przepiorka
D
Weisdorf
D
Martin
P
et al
1994 Consensus Conference on Acute GVHD Grading.
Bone Marrow Transplant
1995
15
6
825
828
9
Inamoto
Y
Ito
M
Suzuki
R
et al
Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy.
Bone Marrow Transplant
2009
44
1
43
49
10
Nishida
T
Hamaguchi
M
Hirabayashi
N
et al
Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease.
Bone Marrow Transplant
2004
33
11
1143
1150
11
Kennedy
MS
Deeg
HJ
Storb
R
et al
Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: randomized study comparing corticosteroids and cyclosporine.
Am J Med
1985
78
6
978
983
12
Ratanatharathorn
V
Nash
RA
Przepiorka
D
et al
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
Blood
1998
92
7
2303
2314
13
Storb
R
Deeg
HJ
Whitehead
J
et al
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
N Engl J Med
1986
314
12
729
735
14
Lin
MT
Storer
B
Martin
PJ
et al
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.
N Engl J Med
2003
349
23
2201
2210
15
Sugimoto
K
Murata
M
Onizuka
M
et al
Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype.
Int J Hematol
2008
87
5
451
458
16
Remberger
M
Mattsson
J
Hassan
Z
et al
Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
Bone Marrow Transplant
2008
41
4
399
405
17
Lee
KH
Choi
SJ
Lee
JH
et al
Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Haematologica
2005
90
7
939
948
18
Patriarca
F
Sperotto
A
Damiani
D
et al
Infliximab treatment for steroid-refractory acute graft-versus-host disease.
Haematologica
2004
89
11
1352
1359
19
Couriel
D
Saliba
R
Hicks
K
et al
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.
Blood
2004
104
3
649
654
20
Oussoren
C
Storm
G
Role of macrophages in the localisation of liposomes in lymph nodes after subcutaneous administration.
Int J Pharm
1999
183
1
37
41
21
Van Rooijen
N
Sanders
A
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications.
J Immunol Methods
1994
174
1
83
93
22
Liu
Q
Hamblin
MR
Macrophage-targeted photodynamic therapy: scavenger receptor expression and activation state.
Int J Immunopathol Pharmacol
2005
18
3
391
402
23
Demidova
TN
Hamblin
MR
Macrophage-targeted photodynamic therapy.
Int J Immunopathol Pharmacol
2004
17
2
117
126
Sign in via your Institution